
    
      Cabozantinib will be taken orally once a day in cycles of 28 days (4 weeks). Fulvestrant will
      be given intramuscularly on days 1 and 15 of cycle 1 and on day 1 of all subsequent cycles.

      On Day 1 of each cycle subjects will have the following tests and procedures:

        -  Performance status

        -  Physical exam

        -  Vital signs

        -  Routine blood samples

        -  Blood and urine samples to look at bone markers (Cycle 1 through 6 only)

      Subjects will also have the following additional tests and procedures:

        -  Tumor assessment by Computed Tomography (CT) scan and bone scan at Cycle 3, then every
           12 weeks

        -  Blood or urine pregnancy test (if applicable) on Day 1 of Cycles 1, 2, 4, then every 12
           weeks

        -  Urine sample and blood test for thyroid function (Cycle 1, 3, 5, then every 6 weeks)

        -  Blood test for breast cancer tumor marker (Cycle 1 and 4, then every 6 weeks)

        -  Pain questionnaire and painkiller medication diary at 7-day intervals during Week 3,
           Week 6, and every 6 weeks thereafter.
    
  